Results: A total of 248 therapy cycles were performed in 145 patients. Data for biochemical
response in 99 patients as well as data for physician-reported and laboratory-based toxicity …

177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …

Purpose The present study summarizes the first experience with 177 Lu-PSMA-617 (177 Lu-
PSMA) treatment in metastatic castration-resistant prostate cancer (PCa) in our institution …

Objective To examine the clinical benefit of Lu-177-PSMA-617 radioligand therapy for
patients with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods …

Abstract Purpose [177 Lu] Lu-PSMA-617 radio-ligand therapy (PSMA-RLT) is emerging in
patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here …

Purpose Preliminary data from retrospective analyses and recent data from large
randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) …

Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific
membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration …

155 Background: Prostate specific membrane antigen (PSMA) is a promising target for
imaging and therapy of prostate cancer. Small cohorts trials have shown promising results …

Purpose The aim of this study was to evaluate the efficacy and safety of 177 Lu-PSMA-617
radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). Methods In …

Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …